EBV+ PTLD: Epstein-Barr virus positive post-transplant lymphoproliferative disease

EBV+ PTLD Pathogenesis

Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) is a rare, acute and potentially life-threatening group of lymphoid disorders that arise after transplantation^3,4.

DNA, deoxyribonucleic acid; EBV+, Epstein-Barr virus positive; PTLD, post-transplant lymphoproliferative disease

PROGNOSIS

The poor patient prognosis associated with EBV+ PTLD upon rituximab-based treatment failure calls for an urgent intervention^5,6.

In post HCT, the median OS post rituximab +/- chemotherapy failure is 0.7 months⁵

In post SOT, the median OS post rituximab +/- chemotherapy failure is 4.1 months⁶

*Survival was measured from the earliest date when patients became refractory or relapsed to rituximab ± CT.
CI, confidence interval; CT, chemotherapy; EBV+, Epstein-Barr virus positive; HCT, haematopoietic cell transplantation; OS, overall survival; PTLD, post-transplant lymphoproliferative disease; SOT, solid organ transplantation.

References

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

1. Mahadeo, K.M. et al. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr viruspositive post-transplant lymphoproliferative disease after failure of Rituximab or rituximab and chemotherapy (allele): A phase 3, Multicentre,
open-label trial. The Lancet Oncology, January 2024.
2. EBVALLO Summary of Product Characteristics.
3. Dierickx D, et al. Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018;378:549–562.
4. Nijland ML, et al. Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct. 2016;2(1):e48.
5. Sanz J, et al. Abstract 1454. Presented at: ASH Annual Meeting and Exposition; December 11–14, 2021; Atlanta. Clinical Outcomes of Patients with Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab:A Multinational, Retrospective Chart Review Study. Blood. 2021;138(Suppl 1):1454.
6. Dharnidharka V, et al. Abstract 2528. Presented at: ASH Annual Meeting and Exposition; December 11–14, 2021; Atlanta. Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study. Blood. 2021;138(Suppl 1):2528.
7. EBVALLO EPAR.

This is an international website for EBVALLO®. IMPORTANT: This material was developped in compliance with EFPIA code and EBVALLO EU SmPC. Registration conditions and prescribing information may vary per country. Therefore, before prescribing any product, Health Care Providers must refer to their country's prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

Last update: 04/2024